These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1768631)

  • 1. Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia.
    Pavlovsky S; Fernández I; Palau V; Santarelli MT; De Bellis R; Ruiz-Argüelles G; Brandalise S; Jiménez-Fonseca E
    Ann Oncol; 1991 Jun; 2(6):441-2. PubMed ID: 1768631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
    Peters WG; Willemze R; Colly LP
    Eur J Haematol; 1988 Mar; 40(3):198-204. PubMed ID: 3162718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
    Jehn U; Heinemann V
    Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin in refractory acute leukemia.
    Fülle HH; Hellriegel KP
    Onkologie; 1986 Jun; 9(3):152-3. PubMed ID: 3528962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of childhood acute nonlymphocytic leukemia with high-dose cytosine arabinoside, 6-thioguanine, and doxorubicin without maintenance therapy: pilot study ANLL-80 of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; Hhlen K; Colly LP; Vossen JM
    Pediatr Hematol Oncol; 1988; 5(2):93-102. PubMed ID: 3152962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
    Lazarus HM; Vogler WR; Burns CP; Winton EF
    Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia.
    Fenaux P; Tertian G; Castaigne S; Tilly H; Leverger G; Guy H; Bordessoule D; Leblay R; Le Gall E; Colombat P
    J Clin Oncol; 1991 Sep; 9(9):1556-61. PubMed ID: 1805818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.
    Liang R; Chiu E; Chan TK; Todd D
    Cancer Chemother Pharmacol; 1990; 26(5):380-2. PubMed ID: 2208581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
    Wells RJ; Gold SH; Krill CE; Cornelius AS; Byrd RL; Ruymann FB; Feusner J; White ML; Cairo MS
    Leukemia; 1994 Oct; 8(10):1626-30. PubMed ID: 7934157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
    Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ
    J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
    Willemze R; Peters WG; van Hennik MB; Fibbe WE; Kootte AM; van Berkel M; Lie R; Rodenburg CJ; Veltkamp JJ
    Scand J Haematol; 1985 Jan; 34(1):83-7. PubMed ID: 3855571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
    Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
    Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Induction and intensive combined therapy of acute myeloid leukemia in adults].
    Kurrle E; Ehninger G; Freund M; Heil G; Hoelzer D; Link H; Mitrou PS; Ohl S; Queisser W; Schlimok G
    Onkologie; 1988 Feb; 11(1):5-9. PubMed ID: 3283626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
    Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
    Taguchi H; Kubonishi I; Takehara N; Uemura Y; Iwahara Y; Eguchi T; Miyagi T; Sugito S; Muneishi H; Tanaka Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1309-14. PubMed ID: 1503485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.